Vinge advised Pricer AB on the deal. Pricer AB (publ) completed its issuance of floating rate senior unsecured bonds of SEK 300 million within a framework...
You must be a Standard 1 Year member to access this content.
Vinge advised Xspray Pharma on the deal. Xspray Pharma AB (publ) completed a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135...
You must be a Standard 1 Year member to access this content.
Vinge advised Egetis Therapeutics on the deal. Egetis Therapeutics AB (publ), listed on Nasdaq Stockholm, completed a directed share issuances whereby Egetis Therapeutics receives gross proceeds...
You must be a Standard 1 Year member to access this content.
Vinge advised Cinclus Pharma on the deal. Cinclus Pharma Holding AB (publ) secured an offering of new ordinary shares and listing on Nasdaq Stockholm. The offering...
You must be a Standard 1 Year member to access this content.
Vinge advised Calliditas Therapeutics on the deal. Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas...
You must be a Standard 1 Year member to access this content.
Vinge advised Pareto Securities on the offering. Episurf Medical secured rights issue of units of up to approximately SEK 120 million. Episurf Medical is a Swedish,...
You must be a Standard 1 Year member to access this content.
Vinge advised Hansa Biopharma AB on the deal. Hansa Biopharma AB (publ) finalized a directed share issue through which the company raises proceeds of SEK 372 million...
You must be a Standard 1 Year member to access this content.
Vinge advised Vimian Group AB on the offering. Vimian Group AB (publ) partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633...
You must be a Standard 1 Year member to access this content.
Vinge advised Oncopeptides AB on the deal. Oncopeptides AB (publ) finalized a fully guaranteed rights issuance which will provide Oncopeptides with issue proceeds of approximately SEK...
You must be a Standard 1 Year member to access this content.
Vinge advised Precio Fishbone AB on the deal. Precio Fishbone AB (publ) completed the sale of approximately 80.1 per cent of the shares in the subsidiary...
You must be a Standard 1 Year member to access this content.
Vinge advised Cell Impact AB on the deal. Cell Impact AB (publ) completed a rights issuance which will provide Cell Impact with issue proceeds of SEK 129...
You must be a Standard 1 Year member to access this content.
Vinge advised Egetis Therapeutics AB on the deal. Egetis Therapeutics AB (publ), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization...
You must be a Standard 1 Year member to access this content.
